Chapel Hill drug developer Cempra Pharmaceuticals announced Tuesday that it could receive up to $58 million from the U.S. government to develop its promising antibiotic treatment.
The five-year contract is with the Biomedical Advanced Research and Development Authority, a division of U.S. Department of Health and Human Services.
It calls for the development of Cempra's experimental drug, solithromycin, to treat infections in pediatric populations and for the treatment of infections caused by bioterrorism.
The authority's contract with Cempra is the second its announced in less than a week. Last week, GlaxoSmithKline announced that it could receive as much as $200 million from the authority to support the development of antibiotics to fight antibiotic resistance and bioterrorism.